Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.740
+0.340 (14.17%)
At close: Nov 4, 2026, 4:00 PM EST
2.760
+0.020 (0.73%)
After-hours: Nov 4, 2026, 7:55 PM EST
Ovid Therapeutics Employees
Ovid Therapeutics had 23 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Ovid Therapeutics the 38,008th largest employer in the world and 5,448th in the United States.
Employees
23
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$68,826
Profits / Employee
-$1,499,000
Market Cap
535.12M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 23 | 0 | - |
| Dec 31, 2024 | 23 | -17 | -42.50% |
| Sep 30, 2024 | 25 | -14 | -35.90% |
| Jun 30, 2024 | 40 | 0 | - |
| Mar 31, 2024 | 40 | -6 | -13.04% |
| Dec 31, 2023 | 40 | -4 | -9.09% |
| Sep 30, 2023 | 39 | -5 | -11.36% |
| Jun 30, 2023 | 40 | -4 | -9.09% |
| Mar 31, 2023 | 46 | -3 | -6.12% |
| Dec 31, 2022 | 44 | -13 | -22.81% |
| Sep 30, 2022 | 44 | -1 | -2.22% |
| Jun 30, 2022 | 44 | -16 | -26.67% |
| Mar 31, 2022 | 49 | -15 | -23.44% |
| Dec 31, 2021 | 57 | -10 | -14.93% |
| Sep 30, 2021 | 45 | -20 | -30.77% |
| Jun 30, 2021 | 60 | 0 | - |
| Mar 31, 2021 | 64 | -1 | -1.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Gyre Therapeutics | 625 |
| Phathom Pharmaceuticals | 371 |
| REGENXBIO | 371 |
| Arvinas | 246 |
| CytomX Therapeutics | 69 |
| Oculis Holding AG | 60 |
| Eupraxia Pharmaceuticals | 49 |
OVID News
- 20 days ago - Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer - PRNewsWire
- 20 days ago - Ovid Therapeutics initiated with an Outperform at Wolfe Research - TheFly
- 26 days ago - Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 26 days ago - Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 4 weeks ago - Ovid Therapeutics management to meet with B. Riley - TheFly
- 4 weeks ago - Guggenheim starts Ovid Therapeutics with a Buy on OV329 potential - TheFly
- 4 weeks ago - Ovid Therapeutics initiated with a Buy at Guggenheim - TheFly
- 7 weeks ago - Ovid Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts